Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: intranasal spray with oxytocin Clear all
Completed Phase 1Phase 2 Interventional Results available

Intranasal Oxytocin for Infants With Prader-Willi Syndrome

NCT03245762
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
1 Week to 6 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Inhaled Oxytocin and HPA Axis Reactivity

NCT03593473
View directory record Official record
Conditions
Depression, Postpartum, Anxiety Disorders, Stress, Psychological
Interventions
Intranasal Oxytocin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 2, 2026, 2:31 AM EDT
Recruiting Phase 2 Interventional

Oxytocin Effects on Bone in Children With Autism Spectrum Disorder

NCT05754073
View directory record Official record
Conditions
Autism Spectrum Disorder, Bone Health
Interventions
1. Intranasal oxytocin spray, 2. Intranasal placebo spray, 3. Intranasal Oxytocin spray
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
6 Years to 18 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Wellness Behaviors as a Function of Oxytocin vs Placebo

NCT01929161
View directory record Official record
Conditions
Sustained Positive Emotions, Sustained Positive Behavior Change
Interventions
Oxytocin, Placebo (for oxytocin), Lovingkindness Meditation, Mindfulness Meditation
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
35 Years to 64 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 2, 2026, 2:31 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Triadic Interactions of Families With Autism and Oxytocin

NCT01912378
View directory record Official record
Conditions
Autism Disorder
Interventions
Oxytocin, Placebo nasal spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
7 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 2, 2026, 2:31 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

NCT06364228
View directory record Official record
Conditions
Stress
Interventions
Placebo, Oxytocin Intranasal Spray 12 International Unit (12IU), Oxytocin Intranasal Spray 24 International Unit (24IU), Functional MRI
Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Biology of Resilience

NCT01011465
View directory record Official record
Conditions
Oxytocin, Placebo
Interventions
intranasal oxytocin, Placebo, Social support, No Social Support
Drug · Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
22 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Effects of Oxytocin Nasal Spray on Social Affiliation

NCT00663039
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors

NCT01944046
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Double blind phase Placebo Nasal Spray, double Blind Oxytocin Nasal Spray, Open Label intranasal oxytocin
Drug
Lead sponsor
Linmarie Sikich
Other
Eligibility
3 Years to 17 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • White Plains, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biological Basis of Individual Variation in Social Cooperation

NCT01566539
View directory record Official record
Conditions
Healthy
Interventions
Intranasal Oxytocin (OT) 24 IU, Intranasal Vasopressin (AVP), Intranasal Placebo, Intranasal Vasopressin (AVP) 40 IU, Lorazepam
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Results available

Oxytocin, Stress, Craving, Opioid Use Disorder

NCT04051619
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
intranasal oxytocin, 40 IU, twice a day for 7 days
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep

NCT03148899
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Oxytocin Intranasal Spray, Placebo Intranasal Spray
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Oxytocin and Learning in Autism

NCT01417026
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Intranasal Oxytocin (Trade name: Syntocinon)
Drug
Lead sponsor
Robert Schultz
Other
Eligibility
12 Years to 17 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin to Treat PTSD

NCT04228289
View directory record Official record
Conditions
PTSD
Interventions
Oxytocin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
San Francisco, California • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Early Phase 1 Interventional

Oxytocin and Cognitive Control in Adult ADHD

NCT03136263
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Oxytocin nasal spray, Placebo nasal spray
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Oxytocin for the Treatment of Alcohol Use Disorder

NCT03878316
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Misuse
Interventions
Instranasal Oxytocin
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Preventing Postpartum Depression With Intranasal Oxytocin

NCT02505984
View directory record Official record
Conditions
Depression, Postpartum, Anxiety
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional

Brain Imaging of Intranasal Oxytocin Treatment in Autism

NCT01945957
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Oxytocin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Not applicable Interventional Results available

Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?

NCT01312272
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Inactive placebo nasal spray
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Oxytocin Treatment for Social Deficits in Children With Autism

NCT01624194
View directory record Official record
Conditions
Autism
Interventions
Oxytocin nasal spray, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 2, 2026, 2:31 AM EDT
Withdrawn Phase 2 Interventional

Intranasal Oxytocin and Learning in Autism

NCT02090829
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Syntocinon (synthetic oxytocin), Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Stimulant Oxytocin Study

NCT03016598
View directory record Official record
Conditions
Stimulant Use & Co-occuring Opioid Use Disorders
Interventions
Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Sacramento, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders

NCT01631682
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Anxiety Disorder
Interventions
Propranolol, Reactivation, Mifepristone, Intranasal oxytocin
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Social Safety Learning in the Brain Oxytocin System

NCT05968651
View directory record Official record
Conditions
Social Phobia
Interventions
Oxytocin nasal spray or placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 2, 2026, 2:31 AM EDT